Scientists reported this week for the first time a Danish reference genome based on the de novo assembly of 150 genomes from 50 family trios.
The company, a division of BGI Group, sold 40.1 million shares at RMB 13.64 per share for a total of RMB 547 million ($80.6 million) in the offering.
NGeneBio is moving ahead with plans to have the test cleared for diagnostic use in Korea, while envisioning a 2019 submission to the US FDA.
BGI won't be selling the gene-edited miniaturized pigs it developed, according to Technology Review.
The partners will explore the possibility of building a sequencing hub at the university for conducting local population cohort studies and diagnostic testing.
Later this year, BGI Europe and its partner Genome Diagnostics Nijmegen plan to offer complete diagnostic exome sequencing including clinical interpretation.
By combining in vivo and in vitro proximity ligation technologies, highly accurate and contiguous genomes can help accelerate more traditional, genetic-marker based crop breeding.
The potential cross-Pacific partnership could help the Seattle-based research institute discover and define cell types in the human brain.
BGI showed that its BGISEQ-500 can sequence a human genome, and that compared to the HiSeq 2500 it is comparable for SNP calling but worse for indels.
A brief recap of Genetics/Genomics news the week of Mar 17, 2017: BGI, Agilent Technologies, ReadCoor, and GeneNews
23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.
By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.
NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.
In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.